» Articles » PMID: 17459698

Endogenous Inhibitors (GALFs) of 11beta-hydroxysteroid Dehydrogenase Isoforms 1 and 2: Derivatives of Adrenally Produced Corticosterone and Cortisol

Overview
Date 2007 Apr 27
PMID 17459698
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Two isoforms of 11beta-HSD exist; 11beta-HSD1 is bi-directional (the reductase usually being predominant) and 11beta-HSD2 functions as a dehydrogenase, conferring kidney mineralocorticoid specificity. We have previously described endogenous substances in human urine, "glycyrrhetinic acid-like factors (GALFs)", which like licorice, inhibit the bi-directional 11beta-HSD1 enzyme as well as the dehydrogenase reaction of 11beta-HSD2. Many of the more potent GALFs are derived from two major families of adrenal steroids, corticosterone and cortisol. For example, 3alpha5alpha-tetrahydro-corticosterone, its derivative, 3alpha5alpha-tetrahydro-11beta-hydroxy-progesterone (produced by 21-deoxygenation of corticosterone in intestinal flora); 3alpha5alpha-tetrahydro-11beta-hydroxy-testosterone (produced by side chain cleavage of cortisol); are potent inhibitors of 11beta-HSD1 and 11beta-HSD2-dehydrogenase, with IC50's in range 0.26-3.0 microM, whereas their 11-keto-3alpha5alpha-tetrahydro-derivatives inhibit 11beta-HSD1 reductase, with IC50's in range 0.7-0.8 microM (their 3alpha5beta-derivatives being completely inactive). Inhibitors of 11beta-HSD2 increase local cortisol levels, permitting it to act as a mineralocorticoid in kidney. Inhibitors of 11beta-HSD1 dehydrogenase/11beta-HSD1 reductase serve to adjust the set point of local deactivation/reactivation of cortisol in vascular and other glucocorticoid target tissues, including adipose, vascular, adrenal tissue, and the eye. These adrenally derived 11-oxygenated C21- and C19 -steroidal substances may serve as 11beta-HSD1- or 11beta-HSD2-GALFs. We conclude that adrenally derived products are likely regulators of local cortisol bioactivity in humans.

Citing Articles

The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers.

Tezuka Y, Ito S Curr Hypertens Rep. 2022; 24(7):215-224.

PMID: 35488944 PMC: 9300503. DOI: 10.1007/s11906-022-01177-6.


Novel metabolomic profile of subjects with non-classic apparent mineralocorticoid excess.

Tapia-Castillo A, Carvajal C, Lopez-Cortes X, Vecchiola A, Fardella C Sci Rep. 2021; 11(1):17156.

PMID: 34433879 PMC: 8387493. DOI: 10.1038/s41598-021-96628-6.


Gut feelings about bacterial steroid-17,20-desmolase.

Ly L, Doden H, Ridlon J Mol Cell Endocrinol. 2021; 525:111174.

PMID: 33503463 PMC: 8886824. DOI: 10.1016/j.mce.2021.111174.


Gut Microbiota and Host Plasma Metabolites in Association with Blood Pressure in Chinese Adults.

Wang Y, Wang H, Howard A, Tsilimigras M, Avery C, Meyer K Hypertension. 2020; 77(2):706-717.

PMID: 33342240 PMC: 7856046. DOI: 10.1161/HYPERTENSIONAHA.120.16154.


The and genes from ATCC 35704 encode steroid-17,20-desmolase.

Devendran S, Mythen S, Ridlon J J Lipid Res. 2018; 59(6):1005-1014.

PMID: 29572237 PMC: 5983398. DOI: 10.1194/jlr.M083949.